01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – Director/PDMR Shareholding June 25, 2025 – Posted in: Poolbeg Pharma (POLB)

25 June 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced  on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price).  Following the AGM earlier this week, the New Ordinary Shares issued pursuant…

Continue reading

#POLB Poolbeg Pharma PLC – Result of upsized oversubscribed BookBuild Offer May 23, 2025 – Posted in: Poolbeg Pharma (POLB)

Result of upsized and oversubscribed BookBuild Offer ·      Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer ·      Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million ·      Use of net proceeds from the Fundraising: o  Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) o  Oral GLP-1 proof-of-concept clinical trial o  Cash runway extended through to 2027 Poolbeg Pharma…

Continue reading

#VELA investee co. #ENSI EnSilica PLC – New Debt Facility November 4, 2024 – Posted in: Uncategorized

EnSilica, a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce that it has secured a new debt facility to refinance its existing external loan facilities, providing total funding of up to £9 million and extending out to November 2029 (the “Facility”).   The Facility has been agreed with Lloyds Bank Group plc, providing the Company with additional flexibility to underpin ongoing working capital commitments, and ensuring that EnSilica…

Continue reading

Open Orphan – Result of General Meeting June 11, 2020 – Posted in: Open Orphan (ORPH)

Thursday 11th June, 2020 Open Orphan plc (“Open Orphan”, or the “Company”) Result of General Meeting Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Fundraising, all of the Resolutions put to the meeting were duly passed. The Conditional…

Continue reading